Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

Impact · against what's priced in

The news is largely non-catalytic for Kimberly-Clark as the market continues to discount the Kenvue acquisition's benefits. While the article highlights Kenvue's strong fundamentals and the tight arbitrage window, these factors are already reflected in its current trading price.

KMB+0.00

Already priced in

The price assumes

the China regulatory delay

The article confirms the deal is pending foreign regulator sign-off for a Q4 2026 close, which aligns with the market's current refusal to price in the acquisition's cost savings.